Proteomic characterization of post-translational modifications in drug discovery
文献类型：期刊论文
| 作者 | Zhai, Lin-hui1,2,3; Chen, Kai-feng1,2; Hao, Bing-bing1; Tan, Min-jia1,2,3
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2022-11-13 |
| 页码 | 18 |
| ISSN号 | 1671-4083 |
| 关键词 | proteomics protein post-translational modification drug target off-target drug mechanism precision medicine |
| DOI | 10.1038/s41401-022-01017-y |
| 通讯作者 | Tan, Min-jia(mjtan@simm.ac.cn) |
| 英文摘要 | Protein post-translational modifications (PTMs), which are usually enzymatically catalyzed, are major regulators of protein activity and involved in almost all celluar processes. Dysregulation of PTMs is associated with various types of diseases. Therefore, PTM regulatory enzymes represent as an attractive and important class of targets in drug research and development. Inhibitors against kinases, methyltransferases, deacetyltransferases, ubiquitin ligases have achieved remarkable success in clinical application. Mass spectrometry-based proteomics technologies serve as a powerful approach for system-wide characterization of PTMs, which facilitates the identification of drug targets, elucidation of the mechanisms of action of drugs, and discovery of biomakers in personalized therapy. In this review, we summarize recent advances of proteomics-based studies on PTM targeting drugs and discuss how proteomics strategies facilicate drug target identification, mechanism elucidation, and new therapy development in precision medicine. |
| WOS关键词 | INTEGRATED PROTEOGENOMIC CHARACTERIZATION ; BET BROMODOMAIN INHIBITORS ; HISTONE LYSINE ; PROTEIN-PHOSPHORYLATION ; QUANTITATIVE PROTEOMICS ; SELECTIVE DEGRADATION ; MOLECULAR-MECHANISM ; MASS-SPECTROMETRY ; UBIQUITIN LIGASE ; HDAC INHIBITORS |
| 资助项目 | Basic research projects of Shanghai Science and Technology Commission science and technology innovation action plan[19JC1416300] ; National Natural Science Foundation of China[32071432] ; National Natural Science Foundation of China[32171434] ; Youth Science and Technology Talents in Shanghai Sail Plan of China[21YF1456000] ; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China[KF-202201] ; Innovative Research Team of High-Level Local Universities in Shanghai[SHSMU-ZDCX20212700] ; Guangdong High-level new RD institute[2019B090904008] ; Guangdong High-level Innovative Research Institute[2021B0909050003] ; Program of Shanghai Academic Research Leader[22XD1420900] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | NATURE PUBL GROUP |
| WOS记录号 | WOS:000882742800002 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/304701]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Tan, Min-jia |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Medica, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Medica, Zhongshan Inst Drug Discovery, Zhongshan 528400, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhai, Lin-hui,Chen, Kai-feng,Hao, Bing-bing,et al. Proteomic characterization of post-translational modifications in drug discovery[J]. ACTA PHARMACOLOGICA SINICA,2022:18. |
| APA | Zhai, Lin-hui,Chen, Kai-feng,Hao, Bing-bing,&Tan, Min-jia.(2022).Proteomic characterization of post-translational modifications in drug discovery.ACTA PHARMACOLOGICA SINICA,18. |
| MLA | Zhai, Lin-hui,et al."Proteomic characterization of post-translational modifications in drug discovery".ACTA PHARMACOLOGICA SINICA (2022):18. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。